Spots Global Cancer Trial Database for refractory hodgkin lymphoma

Every month we try and update this database with for refractory hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT03013933	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Cyclosporine Pharmacokinetic... Verapamil Verapamil Hydro...	15 Years -	City of Hope Medical Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients	NCT02098512	Hodgkin Lymphom...	Brentuximab Ved... Allogeneic Stem... Reduced Intensi...	- 45 Years	New York Medical College
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	NCT03259503	Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce...	Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat	18 Years - 65 Years	M.D. Anderson Cancer Center
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT01572519	Relapsed or Ref...	Phase 1, Cohort... Phase 1, Cohort... Phase 1, Cohort... Phase 1, Cohort... Phase 2	18 Years -	Janssen Research & Development, LLC
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma	NCT05137886	Hodgkin Lymphom... Relapse Refractory Hodg...	PD-1 inhibitor	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma	NCT02456675	Refractory Hodg... Recurrent Adult...	INCB040093 Mono... INCB040093 itacitinib	18 Years -	Incyte Corporation
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma	NCT05595447	Hodgkin Lymphom... Refractory Hodg... Relapsed Hodgki...	Brentuximab Ved...	15 Years - 90 Years	Hospital Regional de Alta Especialidad del Bajio
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02254239	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological...	18 Years -	Mayo Clinic
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02254239	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological...	18 Years -	Mayo Clinic
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	NCT02869633	Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant...	Ibrutinib Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma	NCT04640779	Recurrent Histi... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Refractory Hist... Refractory Hodg... Refractory Non-... Refractory Plas...	Choline Salicyl... Selinexor	18 Years -	Mayo Clinic
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT02824029	Classical Hodgk... Recurrent Hodgk... Refractory Hodg...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	NCT05272384	Recurrent B-Cel... Recurrent Diffu... Recurrent Hodgk... Refractory B-Ce... Refractory Diff... Refractory Hodg...	Biospecimen Col... Computed Tomogr... Decitabine and ... Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	NCT01231412	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Lymphoc... Diffuse Large B... Hematopoietic a... Indolent Non-Ho... Mantle Cell Lym... Myelodysplastic... Myeloproliferat... Prolymphocytic ... Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Chro... Refractory Hodg... Small Lymphocyt... T-Cell Chronic ... Waldenstrom Mac...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02227199	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Carboplatin Etoposide Ifosfamide Laboratory Biom...	18 Years -	University of Washington
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma	NCT02456675	Refractory Hodg... Recurrent Adult...	INCB040093 Mono... INCB040093 itacitinib	18 Years -	Incyte Corporation
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma	NCT01393717	Recurrent Hodgk... Refractory Hodg...	brentuximab ved...	11 Years -	City of Hope Medical Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	NCT00005803	Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph...	Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02254239	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological...	18 Years -	Mayo Clinic
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	NCT01703949	Recurrent Hodgk... Recurrent Non-H... Refractory Hodg... Refractory Non-...	Brentuximab Ved... Laboratory Biom... Nivolumab	18 Years -	University of Washington
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	NCT01897012	MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu...	Alisertib Laboratory Biom... Romidepsin	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL	NCT04938232	Hodgkin Lymphom... Relapsed Hodgki... Refractory Hodg...	Nivolumab Ipilimumab	18 Years -	Dana-Farber Cancer Institute
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	NCT00789776	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Diffuse Large B... Previously Trea... Recurrent Chron... Recurrent Chron... Recurrent Indol... Recurrent Mantl... Recurrent Plasm... Recurrent Small... Refractory Chro... Refractory Hodg... Refractory Plas... Refractory Smal... Waldenstrom Mac...	Allogeneic Bone... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Mycophenolate M... Natural Killer ... Tacrolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	NCT00005803	Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph...	Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	NCT01921387	Recurrent B-Cel... Recurrent Hodgk... Recurrent Mantl... Recurrent T-Cel... Refractory B-Ce... Refractory Hodg... Refractory Mant... Refractory T-Ce...	Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Melphalan Peripheral Bloo... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT04052997	Relapsed Hodgki... Refractory Hodg...	Camidanlumab Te...	16 Years -	ADC Therapeutics S.A.
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	NCT00860171	Recurrent B-Cel... Recurrent Hodgk... Recurrent T-Cel... Refractory B-Ce... Refractory Hodg... Refractory T-Ce...	Autologous Hema... Iodine I 131 Mo... Laboratory Biom...	18 Years -	Fred Hutchinson Cancer Center
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma	NCT05137886	Hodgkin Lymphom... Relapse Refractory Hodg...	PD-1 inhibitor	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT02824029	Classical Hodgk... Recurrent Hodgk... Refractory Hodg...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma	NCT00742027	Classical Hodgk...	Panobinostat	18 Years -	Novartis
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT02824029	Classical Hodgk... Recurrent Hodgk... Refractory Hodg...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	NCT01703949	Recurrent Hodgk... Recurrent Non-H... Refractory Hodg... Refractory Non-...	Brentuximab Ved... Laboratory Biom... Nivolumab	18 Years -	University of Washington
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	NCT03259503	Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce...	Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat	18 Years - 65 Years	M.D. Anderson Cancer Center
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma	NCT04871607	Recurrent Hodgk... Refractory Hodg...	Basiliximab Carmustine Cytarabine Etoposide Genetically Eng... Recombinant Gra... Yttrium Y 90 Ba...	18 Years -	City of Hope Medical Center
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma	NCT04640779	Recurrent Histi... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Refractory Hist... Refractory Hodg... Refractory Non-... Refractory Plas...	Choline Salicyl... Selinexor	18 Years -	Mayo Clinic
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL	NCT03016871	Recurrent Hodgk... Refractory Hodg...	Carboplatin Etoposide Ifosfamide Laboratory Biom... Nivolumab	18 Years -	City of Hope Medical Center
Intra-Osseous Co-Transplant of UCB and hMSC	NCT02181478	Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Myelofibrosis Relapsed Non-Ho... Refractory Non-... Hodgkin Lymphom... Refractory Hodg... Relapsed Chroni... Refractory Chro... Lymphoid Malign... Chronic Myeloge...	cyclophosphamid... fludarabine pho... total-body irra... cyclosporine mycophenolate m... umbilical cord ... mesenchymal ste...	18 Years - 75 Years	Case Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: